Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis

Area of Science:

• Biopharmaceutical drug development
• Immunology
• Neurology

Background:

• Biopharmaceuticals, derived from natural sources, can elicit an immunogenic response, leading to anti-drug antibodies (ADAs).
• ADA formation can neutralize biopharmaceutical activity, diminishing treatment efficacy and potentially causing hypersensitivity reactions.
• Interferon-beta (IFNβ) is a primary treatment for multiple sclerosis (MS), but its efficacy can be impacted by immunogenicity.

Purpose of the Study:

• To review the use of IFNβ in MS treatment.
• To discuss the biological and clinical significance of anti-IFNβ antibodies (binding and neutralizing).
• To explore the incorporation of ADA testing into clinical practice for MS patients.

Main Methods:

• Literature review of studies on IFNβ in MS.
• Analysis of data regarding anti-IFNβ antibody prevalence and impact.
• Discussion of clinical guidelines and ongoing research.

Main Results:

• ADA development in MS patients treated with IFNβ varies widely (2-45%), depending on the specific drug and dosage.
• Anti-IFNβ antibodies are associated with a loss of clinical response and potential hypersensitivity.
• Controversy persists regarding the clinical significance of ADAs and routine testing in MS.

Conclusions:

• The immunogenicity of IFNβ is a significant concern in MS management.
• Understanding the role of anti-IFNβ antibodies is crucial for optimizing treatment strategies.
• Further research is needed to clarify the clinical utility of ADA testing in routine MS care.